文献速递神经核医学

基于CT的区域淀粉样蛋白PET协调方法的临床与病理验证

Clinical and Pathological Validation of CT-Based Regional Harmonization Methods of Amyloid PET.
PubMed 文献 · Clin Nucl Med · 2023-11-29

本研究纳入63例病理队列和4062例临床队列,评估基于CT的区域直接比较Centiloid(dcCL)量表与β-淀粉样蛋白(Aβ)病理负荷的相关性,并利用病理评估得出的阈值验证其临床效用。结果显示区域dcCL量表与mCERAD评分整体和区域相关(r=0.56~0.76),可高精度预测特定脑区显著Aβ沉积,不同阈值下临床表型差异不同。

要点

  • 基于CT的区域dcCL量表与mCERAD评分整体和区域相关(r=0.56~0.76)。
  • 区域dcCL量表预测特定脑区显著Aβ沉积的AUC为0.81-0.97(mCERAD cutoff 1.5)和0.88-0.93(cutoff 0.5)。
  • 应用1.5 mCERAD阈值时,G(-)R(+)组记忆和整体认知表现低于G(-)R(-)组,海马体积更小(P<0.001)。

核心结论

  • 基于病理评估得出的区域dcCL量表阈值可能帮助临床医生更好地理解生物标志物引导的诊断和可区分的临床表型,在仅使用PET/CT协调不同PET配体时尤其有用。

研究设计与样本

  • 研究纳入病理队列63例和临床队列4062例,通过评估每个皮层区域多个区域的神经炎性斑块负荷获得mCERAD评分。
  • PET和CT图像使用基于CT的区域dcCL方法处理,计算6个不同区域的量表。

主要发现

  • 基于CT的区域dcCL量表与mCERAD评分代表的神经炎性斑块负荷整体和区域相关(r=0.56~0.76)。
  • 纹状体dcCL量表反映纹状体Aβ受累(P<0.001)。
  • 区域dcCL量表可高精度预测特定脑区显著Aβ沉积:mCERAD cutoff 1.5时AUC为0.81-0.97,cutoff 0.5时AUC为0.88-0.93。
  • 应用1.5 mCERAD评分的dcCL阈值时,G(-)R(+)组记忆和整体认知功能表现低于G(-)R(-)组,海马体积更小(P<0.001)。
  • 应用0.5 mCERAD评分的dcCL阈值时,两组整体认知功能无差异。

关键数值与推荐

  • mCERAD cutoff 1.5时,区域dcCL量表预测显著Aβ沉积的AUC为0.81-0.97。
  • mCERAD cutoff 0.5时,区域dcCL量表预测显著Aβ沉积的AUC为0.88-0.93。
  • dcCL阈值对应1.5 mCERAD评分时,G(-)R(+)组较G(-)R(-)组记忆和整体认知功能表现更低、海马体积更小(P<0.001)。
  • dcCL阈值对应0.5 mCERAD评分时,两组整体认知功能无差异。

临床怎么用

  • 原文结论指出,基于病理评估的区域dcCL量表阈值可能帮助临床医生更好地理解生物标志物引导的诊断和可区分的临床表型,在仅使用PET/CT协调不同PET配体时尤其有用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The CT-based regional direct comparison Centiloid (dcCL) method was developed to harmonize and quantify regional β-amyloid (Aβ) burden. In the present study, we aimed to investigate correlations between the CT-based regional dcCL scales and Aβ pathological burdens and to validate the clinical utility using thresholds derived from pathological assessment. PATIENTS AND METHODS: We included a pathological cohort of 63 cases and a clinical cohort of 4062 participants, and obtained modified Consortium to Establish a Registry for Alzheimer's Disease criteria (mCERAD) scores by assessment of neuritic plaque burdens in multiple areas of each cortical region. PET and CT images were processed using the CT-based regional dcCL method to calculate scales in 6 distinct regions. RESULTS: The CT-based regional dcCL scales were correlated with neuritic plaque burdens represented by mCERAD scores, globally and regionally ( r = 0.56~0.76). In addition, striatum dcCL scales reflected Aβ involvement in the striatum ( P < 0.001). The regional dcCL scales could predict significant Aβ deposition in specific brain regions with high accuracy: area under the receiver operating characteristic curve of 0.81-0.97 with an mCERAD cutoff of 1.5 and area under the receiver operating characteristic curve of 0.88-0.93 with an mCERAD cutoff of 0.5. When applying the dcCL thresholds of 1.5 mCERAD scores, the G(-)R(+) group showed lower performances in memory and global cognitive functions and had less hippocampal volume compared with the G(-)R(-) group ( P < 0.001). However, when applying the dcCL thresholds of 0.5 mCERAD scores, there were no differences in the global cognitive functions between the 2 groups. CONCLUSIONS: The thresholds of regional dcCL scales derived from pathological assessments might provide clinicians with a better understanding of biomarker-guided diagnosis and distinguishable clinical phenotypes, which are particularly useful when harmonizing different PET ligands with only PET/CT.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kim SJ, Jang H, Yoo H, et al. Clinical and Pathological Validation of CT-Based Regional Harmonization Methods of Amyloid PET. Clin Nucl Med. 2023. PMID: 38048354. doi:10.1097/RLU.0000000000004937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。